Evidence map›Paper›PMID 30300420›Full record

ArticlePLoS neglected tropical diseases2018

The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis.

Ashraful Islam Khan, Ann Levin, Dennis L Chao, Denise DeRoeck, Dobromir T Dimitrov, Jahangir A M Khan, Muhammad Shariful Islam, Mohammad Ali, Md Taufiqul Islam, Abdur Razzaque Sarker and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Recent epidemiological and management approaches for cholera in India.Proceedings (Baylor University. Medical Center) · 2026
    Review
  5. Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Diagnosis, Management, and Future Control of Cholera.Clinical microbiology reviews · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Mathematical Modeling of Endemic Cholera Transmission.The Journal of infectious diseases · 2021
    Article
  17. Article
  18. Can cholera 'hotspots' be converted to cholera 'coldspots' in cholera endemic countries? The Matlab, Bangladesh experience.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Ashraful Islam KhanInternational Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Ann LevinLevin and Morgan, Washington, DC, United States of America.
Dennis L ChaoInstitute for Disease Modeling Bellevue, WA, United States of America.
Denise DeRoeckIndependent Consultant, Dennison Street, Waltham, Massachusetts, United States of America.
Dobromir T DimitrovVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Jahangir A M KhanLiverpool School of Tropical Medicine, Liverpool, United Kingdom.
Muhammad Shariful IslamInternational Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Mohammad AliJohns Hopkins School of Public Health, Baltimore, Maryland, United States of America.
Md Taufiqul IslamInternational Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Abdur Razzaque SarkerInternational Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
John D ClemensInternational Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Firdausi QadriInternational Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.ORCID 0000-0001-8459-304X
International Centre for Diarrhoeal Disease Research · BDBellevue Hospital Center · USFred Hutch Cancer Center · USJohns Hopkins University · USLiverpool School of Tropical Medicine · GBMorgan, Lewis & Bockius (United States) · USUniversity of Strathclyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCholera remains an important public health problem in major cities in Bangladesh, especially in slum areas. In response to growing interest among local policymakers to control this disease, this study estimated the impact and cost-effectiveness of preventive cholera vaccination over a ten-year period in a high-risk slum population in Dhaka to inform decisions about the use of oral cholera vaccines as a key tool in reducing cholera risk in such populations. METHODOLOGY/PRINCIPAL

findingsAssuming use of a two-dose killed whole-cell oral cholera vaccine to be produced locally, the number of cholera cases and deaths averted was estimated for three target group options (1-4 year olds, 1-14 year olds, and all persons 1+), using cholera incidence data from Dhaka, estimates of vaccination coverage rates from the literature, and a dynamic model of cholera transmission based on data from Matlab, which incorporates herd effects. Local estimates of vaccination costs minus savings in treatment costs, were used to obtain incremental cost-effectiveness ratios for one- and ten-dose vial sizes. Vaccinating 1-14 year olds every three years, combined with annual routine vaccination of children, would be the most cost-effective strategy, reducing incidence in this population by 45% (assuming 10% annual migration), and costing was $823 (2015 USD) for single dose vials and $591 (2015 USD) for ten-dose vials per disability-adjusted life year (DALY) averted. Vaccinating all ages one year and above would reduce incidence by >90%, but would be 50% less cost-effective ($894-1,234/DALY averted). Limiting vaccination to 1-4 year olds would be the least cost-effective strategy (preventing only 7% of cases and costing $1,276-$1,731/DALY averted), due to the limited herd effects of vaccinating this small population and the lower vaccine efficacy in this age group. CONCLUSIONS/SIGNIFICANCE: Providing cholera vaccine to slum populations in Dhaka through periodic vaccination campaigns would significantly reduce cholera incidence and inequities, and be especially cost-effective if all 1-14 year olds are targeted.

Indexed as

Cost-Benefit AnalysisAdolescentAdultAgedAged, 80 and overAge FactorsBangladeshChildChild, PreschoolCholeraCholera VaccinesDisease Transmission, InfectiousFemaleHumansImmunization ScheduleInfantCholera VaccinesVaccines, Inactivated

Identifiers

PMID30300420
PMCPMC6177119
OpenAlexW2896242931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.